Cargando…

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach. APPROACH AND RESULTS: PubMed and Ovid MEDLINE were searched for NAFLD population-based studies from 1990 to 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Younossi, Zobair M., Golabi, Pegah, Paik, James M., Henry, Austin, Van Dongen, Catherine, Henry, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026948/
https://www.ncbi.nlm.nih.gov/pubmed/36626630
http://dx.doi.org/10.1097/HEP.0000000000000004
_version_ 1784909622476275712
author Younossi, Zobair M.
Golabi, Pegah
Paik, James M.
Henry, Austin
Van Dongen, Catherine
Henry, Linda
author_facet Younossi, Zobair M.
Golabi, Pegah
Paik, James M.
Henry, Austin
Van Dongen, Catherine
Henry, Linda
author_sort Younossi, Zobair M.
collection PubMed
description NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach. APPROACH AND RESULTS: PubMed and Ovid MEDLINE were searched for NAFLD population-based studies from 1990 to 2019 survey year (last published 2022) per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Meta-analysis was conducted using random-effects models. Bias risk assessment was per Joanna Briggs Institute. Of 2585 studies reviewed, 92 studies (N=9,361,716) met eligibility criteria. Across the study period (1990–2019), meta-analytic pooling of NAFLD prevalence estimates and ultrasound-defined NAFLD yielded an overall global prevalence of 30.05% (95% CI: 27.88%–32.32%) and 30.69% (28.4–33.09), respectively. Global NAFLD prevalence increased by +50.4% from 25.26% (21.59–29.33) in 1990–2006 to 38.00% (33.71–42.49) in 2016–2019 (p<0.001); ultrasound-defined NAFLD prevalence increased by +38.7% from 25.16% (19.46–31.87) in 1990–2006 to 34.59% (29.05–40.57) (p=0.029). The highest NAFLD prevalence was in Latin America 44.37% (30.66%–59.00%), then Middle East and North Africa (MENA) (36.53%, 28.63%–45.22%), South Asia (33.83%, 22.91%–46.79%), South-East Asia (33.07%, 18.99%–51.03%), North America (31.20%, 25.86%–37.08%), East Asia (29.71%, 25.96%–33.76%), Asia Pacific 28.02% (24.69%–31.60%), Western Europe 25.10% (20.55%–30.28%). Among the NAFLD cohort diagnosed without a liver biopsy, pooled mortality rate per 1000 PY was 12.60 (6.68–23.67) for all-cause mortality; 4.20 (1.34–7.05) for cardiac-specific mortality; 2.83 (0.78–4.88) for extrahepatic cancer-specific mortality; and 0.92 (0.00–2.21) for liver-specific mortality. CONCLUSIONS: NAFLD global prevalence is 30% and increasing which requires urgent and comprehensive strategies to raise awareness and address all aspects of NAFLD on local, regional, and global levels.
format Online
Article
Text
id pubmed-10026948
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-100269482023-03-21 The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review Younossi, Zobair M. Golabi, Pegah Paik, James M. Henry, Austin Van Dongen, Catherine Henry, Linda Hepatology Original Articles: Steatohepatitis NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach. APPROACH AND RESULTS: PubMed and Ovid MEDLINE were searched for NAFLD population-based studies from 1990 to 2019 survey year (last published 2022) per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Meta-analysis was conducted using random-effects models. Bias risk assessment was per Joanna Briggs Institute. Of 2585 studies reviewed, 92 studies (N=9,361,716) met eligibility criteria. Across the study period (1990–2019), meta-analytic pooling of NAFLD prevalence estimates and ultrasound-defined NAFLD yielded an overall global prevalence of 30.05% (95% CI: 27.88%–32.32%) and 30.69% (28.4–33.09), respectively. Global NAFLD prevalence increased by +50.4% from 25.26% (21.59–29.33) in 1990–2006 to 38.00% (33.71–42.49) in 2016–2019 (p<0.001); ultrasound-defined NAFLD prevalence increased by +38.7% from 25.16% (19.46–31.87) in 1990–2006 to 34.59% (29.05–40.57) (p=0.029). The highest NAFLD prevalence was in Latin America 44.37% (30.66%–59.00%), then Middle East and North Africa (MENA) (36.53%, 28.63%–45.22%), South Asia (33.83%, 22.91%–46.79%), South-East Asia (33.07%, 18.99%–51.03%), North America (31.20%, 25.86%–37.08%), East Asia (29.71%, 25.96%–33.76%), Asia Pacific 28.02% (24.69%–31.60%), Western Europe 25.10% (20.55%–30.28%). Among the NAFLD cohort diagnosed without a liver biopsy, pooled mortality rate per 1000 PY was 12.60 (6.68–23.67) for all-cause mortality; 4.20 (1.34–7.05) for cardiac-specific mortality; 2.83 (0.78–4.88) for extrahepatic cancer-specific mortality; and 0.92 (0.00–2.21) for liver-specific mortality. CONCLUSIONS: NAFLD global prevalence is 30% and increasing which requires urgent and comprehensive strategies to raise awareness and address all aspects of NAFLD on local, regional, and global levels. Lippincott Williams & Wilkins 2023-04 2023-01-03 /pmc/articles/PMC10026948/ /pubmed/36626630 http://dx.doi.org/10.1097/HEP.0000000000000004 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Original Articles: Steatohepatitis
Younossi, Zobair M.
Golabi, Pegah
Paik, James M.
Henry, Austin
Van Dongen, Catherine
Henry, Linda
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
title The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
title_full The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
title_fullStr The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
title_full_unstemmed The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
title_short The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
title_sort global epidemiology of nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash): a systematic review
topic Original Articles: Steatohepatitis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026948/
https://www.ncbi.nlm.nih.gov/pubmed/36626630
http://dx.doi.org/10.1097/HEP.0000000000000004
work_keys_str_mv AT younossizobairm theglobalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview
AT golabipegah theglobalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview
AT paikjamesm theglobalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview
AT henryaustin theglobalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview
AT vandongencatherine theglobalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview
AT henrylinda theglobalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview
AT younossizobairm globalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview
AT golabipegah globalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview
AT paikjamesm globalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview
AT henryaustin globalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview
AT vandongencatherine globalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview
AT henrylinda globalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview